Weekly Investment Analysts’ Ratings Changes for Lucid Diagnostics (LUCD)

Several brokerages have updated their recommendations and price targets on shares of Lucid Diagnostics (NASDAQ: LUCD) in the last few weeks:

• 10/14/2025 – Lucid Diagnostics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/14/2025 – Lucid Diagnostics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 10/6/2025 – Lucid Diagnostics had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a “buy” rating on the stock.
• 10/6/2025 – Lucid Diagnostics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 9/28/2025 – Lucid Diagnostics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 9/27/2025 – Lucid Diagnostics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/20/2025 – Lucid Diagnostics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 9/5/2025 – Lucid Diagnostics had its price target raised by analysts at BTIG Research from $2.00 to $2.50. They now have a “buy” rating on the stock.

Insider Activity

In other Lucid Diagnostics news, Director Dennis Matheis bought 100,000 shares of Lucid Diagnostics stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average cost of $1.02 per share, with a total value of $102,000.00. Following the completion of the purchase, the director owned 665,443 shares of the company’s stock, valued at approximately $678,751.86. This represents a 17.69% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.80% of the company’s stock.

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.